Breast Cancer
Conference Coverage
TAILORx marks major advance for precision medicine in breast cancer
CHICAGO – Practice-changing data show that most women with HR-positive, HER2-negative, early-stage breast cancer who have an intermediate...
Conference Coverage
Dr. William J. Gradishar shares breast cancer take-aways from ASCO 2018
CHICAGO – TAILORx is a “big win,” while SANDPIPER results are nothing to get excited about.
Conference Coverage
IMPACT study: Matched targeted therapy improves survival in advanced cancer
Patients with advanced cancer who received matched targeted therapy had better disease control rates, progression-free survival, and overall...
Case-Based Review
HER2-Positive Breast Cancer: Current Management
Conference Coverage
PI3K inhibitor/fulvestrant has modest benefit, serious toxicity in breast cancer
CHICAGO – The combination of talesib/fulvestrant extended PFS by two months, but at a cost of serious toxicities in half of the patients treated...
Video
TAILORx: Most women with intermediate risk ER+ breast cancer can safely skip chemo
CHICAGO - Lead study author Dr. Joseph A. Sparano discusses the implications of the new data for decision-making and future plans for the tumor...
Conference Coverage
Heading down the wrong pathway in advanced breast cancer?
CHICAGO - Dr. Harold Burstein questions whether the PI3K pathway is worth pursuing, despite positive results from SANDPIPER.
Feature
Dr Jame Abraham's top ASCO selections in breast cancer
From the Journals
Ketorolac may reduce breast cancer recurrence risk, particularly in overweight patients
Investigators found a significant association between interoperative ketorolac and decreased incidence of distant metastasis, with reduced...
From the Journals
Screening for brain mets could improve quality of life for some with breast cancer
Compared with NSCLC patients, breast cancer patients presented with larger and more numerous brain mets, resulting in more invasive treatments,...
Conference Coverage
CBT-I bests acupuncture for treating insomnia among cancer survivors
In a randomized trial, both CBT-I and acupuncture reduced insomnia severity among cancer survivors, but the former had the edge.